Alert Banner Warning

New mask policy at AHN facilities

Alert Banner X

Surgical-type, N95, or KN95 face masks are now required within all AHN facilities. Cloth face masks are no longer permitted, as they do not provide the best level of protection against Coronavirus.

Monoclonal Antibody Infusion Therapy

For our high-risk patients, monoclonal antibody infusion therapy can help lessen the severity of COVID-19 symptoms.

This therapy must be given within the first 10 days of COVID-19 symptoms. Contact your AHN provider as soon as you start to feel symptoms or think you’ve been exposed to Coronavirus to coordinate COVID-19 testing. If you have COVID-19 and if you’re eligible, your provider will provide next steps and direct you to the appropriate AHN facility.

What is monoclonal antibody infusion therapy?

Monoclonal antibody infusion therapy uses antibodies administered through an IV to help treat mild to moderate COVID-19 cases in non-hospitalized, high-risk patients. This therapy received emergency use authorization (EUA) from the Food and Drug Administration for use with Coronavirus patients.

We have recently switched to using only Sotrovimab – the monoclonal antibody with effectiveness against the omicron variant of the COVID-19 virus. The omicron variant is currently the dominant variant in the US, and previous formulations of monoclonal antibodies are not effective against it.

Who is eligible for monoclonal antibody infusion therapy?

Because Sotrovimab is in short supply, AHN prioritizes our highest-risk patients, 18 and older, for this therapy. As supplies increase, we will broaden eligibility.

High-risk patients: 

  • Pregnant women
  • Those currently receiving chemotherapy for cancer
  • Transplant recipients
  • Anyone with severe immunosuppression from autoimmune diseases and associated medications
  • People 75 years and older

 Additional criteria:

  • The patient must have a recent COVID-19 diagnosis and be experiencing COVID-19 symptoms for 10 days or less
  • Cannot be currently hospitalized due to COVID-19
  • Cannot require supplemental oxygen due to COVID-19 or require an increase in baseline supplemental oxygen flow rate due to COVID-19 in those on chronic supplemental oxygen

I believe I qualify. How can I get monoclonal antibody infusion therapy?

Call your AHN provider to discuss your appropriate next steps. If you do not have a primary care provider, you can schedule a virtual urgent care visit with AHN.

Is it safe to get monoclonal antibody infusion therapy?

Yes. Monoclonal antibodies have been used in clinical settings for years. Mild side effects have been reported, but are generally uncommon. You’ll also be closely monitored after your infusion for any reactions.

Why should I get monoclonal antibody infusion therapy?

This therapy has been closely studied and can reduce the likelihood of hospitalization or death for COVID-19 patients who have mild to moderate symptoms.

How does monoclonal antibody infusion therapy relate to vaccines and booster doses?

Vaccination and boosters do not affect your eligibility to receive monoclonal antibody infusion therapy. AHN encourages all eligible patients to receive their vaccine or booster.

However, once a patient does receive this therapy, any COVID-19 vaccine dose or booster must be delayed for 90 days.

  • Appointments

    Primary Care
    (412) DOCTORS